Skip to main content
MNKDMannKind CorporationSell6.2·$3.85
MNKD · Why this verdict

Why MannKind (MNKD) is rated SELL

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictSELL
Overall score6.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

MannKind is growing revenue about 24% year over year but remains cash-burning with losses and misses, depends on a sole insulin supplier, and carries weak quality, so the large analyst-target upside is speculative.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

Quality of 3.8 reflects free cash flow at -1% of revenue, a Rule of 40 score of 23 (fail) and an operating margin of -900.1% flagged as margin compression.

→Stable
Quality breakdown
Expectation
Free cash flow turns positive and quarterly EPS returns to at least breakeven.

CounterA negative margin figure that large may reflect one-off items, but a persistent cash burn would pressure the balance sheet.

Revenue grew 24% year over year, with quarterly revenue of $101.9M in September 2026 versus $82.1M a year earlier.

→Stable
Growth breakdown
Expectation
Quarterly revenue reaches the $134M next-quarter estimate and keeps growing above 15% year over year.

CounterRevenue fell sequentially from $109.4M to $101.9M, so the growth path is uneven.

Amphastar is the sole insulin supplier for Afrezza, a HIGH concentration risk to product supply.

→Stable
Bear case
Expectation
Supply continues without interruption and gross margin holds near current levels.

CounterA supply disruption or price increase from a single supplier could halt sales with no alternate source.

EPS missed in 3 of the last 4 quarters, with EPS of -$0.01 to -$0.05 versus estimates of $0.01 to $0.02, after earlier profitable quarters.

↑Improving
Last 4 quarters
Expectation
EPS returns to positive and meets or beats consensus in the next two quarters.

CounterPercentage surprises are large because EPS values are near zero, so small dollar differences exaggerate the misses.

Analyst target of $7.25 versus a $3.85 price implies 88.3% upside, with light analyst coverage and a 41% drawdown from the 52-week high.

↑Improving
Analyst target
Expectation
Price closes part of the gap to the target as revenue growth is converted into profit.

CounterCoverage is light, targets for small biotechs are often cut, and a death cross shows the trend is still down.

Per-dimension breakdown

Value

8.2/10data confidence 67%
ComponentSub-score
P/S8.3
Fwd P/E5.2
PEG10.0
Analyst target9.0
  • ▸Forward P/E: 24.4x
  • ▸PEG: 0.15
  • ▸Attractively valued

Quality

3.8/10data confidence 100%
ComponentSub-score
ROA0.0
Gross margin10.0
Op margin0.0
Net margin0.0
Current ratio7.6
FCF quality0.0
Moat7.0
Rule of 403.0
Piotroski F6.7
  • ▸Cash-burning: FCF -1% of revenue
  • ▸Rule of 40: 23 (fail)

Growth

9.2/10data confidence 67%
ComponentSub-score
Rev growth8.5
EPS growth10.0
  • ▸Strong growth: 24% YoY

Momentum

4.6/10data confidence 100%
ComponentSub-score
RSI5.5
MACD3.8
OBV1.0
MA position8.0
Volume4.8
  • ▸Volume distribution (falling OBV)
  • ▸Above 200-MA but MA slope flat

Sentiment

7.9/10data confidence 100%
ComponentSub-score
LLM sentiment5.7
Analyst rating8.0
Price target10.0
  • ▸Light analyst coverage (9.0) — signal dampened
  • ▸Analyst upside: 116%

Insider

5.9/10data confidence 100%
ComponentSub-score
materiality4.5
insider conviction2.0
holder change10.0
notable moves7.0
  • ▸Modest insider selling — $256,334 (0.021% of mkt cap)
  • ▸Institutions accumulating

Peer rank

5.5/10data confidence 80%
ComponentSub-score
value rank8.0
quality rank3.4
growth rank5.7

Technical

4.2/10data confidence 100%
ComponentSub-score
bollinger4.9
support resistance3.9
52w position1.8
gap6.0

Risk (lower is worse)

4.5/10data confidence 100%
ComponentSub-score
short interest5.9
days to cover4.4
volatility0.0
put call9.9
implied vol0.0
beta6.6
  • ▸High IV: 130%
  • ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

3.2/10data confidence 100%
ComponentSub-score
erm5.0
earnings history0.0
earnings timing5.0
surprise avg0.0
news activity6.0
  • ▸Earnings concerns: 0B/3M

How the verdict was assembled

Engine trigger

Quality below minimum threshold.

Engine technical detail
verdict_path: L1:HARD_BLOCK:QUALITY_FLOOR
Passed (8)
  • MOMENTUM:4.6>=4.5
  • ASYMMETRY:5.9>=1.5
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:95d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
  • DEATH_CROSS:HARD_BLOCK
Warning (1)
  • MOMENTUM:4.6<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
5.89
Upside
+88.3%
Downside
15.0%
Sizing output
AVOID

SetupRange Bound — RSI 57 mid-range, Bollinger mid-band

EdgeInst Constrain — Small cap ($1.2B) below institutional reach

SuitabilitySpeculative — Drawdown -41% (>40% off 52w high), Binary industry: Biotechnology

Investment implication

The SELL_IF_HOLDING verdict reflects the DEATH_CROSS gate's HARD_BLOCK outcome against Growth at 9.2 and asymmetric R:R of 5.89.

The strongest dimensions are Growth at 9.2, Value at 8.2, and Sentiment at 7.9; the weakest are Catalyst at 3.2, Quality at 3.8, and Technical at 4.2. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 5.89 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Strong Revenue Growth

    Trip ifQuarterly revenue growth falls below 10% year over year for 2 consecutive quarters.

  • P2Sole Supplier Dependence

    Trip ifAny Amphastar supply interruption lasts more than 1 quarter.

  • P3Cash Burn Margin Compression

    Trip ifFree cash flow falls below -5% of revenue from the current -1%.

  • P4Earnings Misses Reversing

    Trip ifQuarterly EPS stays below -$0.02 for 2 consecutive quarters.

  • P5Analyst Target Upside Gap

    Trip ifPrice falls below the $3.58 stop level, more than 7% under the current $3.85.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › MNKD › Why this verdict